FPS
MRTX

Fieldpoint Private Securities’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Fieldpoint Private Securities’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$89K Buy
1,333
+635
+91% +$40.4K 0.03% 389
2022
Q1 		$57K Buy
+698
New +$71.4K 0.01% 559

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Fieldpoint Private Securities's MRTX Position: Q2 2022 in Review

Fieldpoint Private Securities increased its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 91% in Q2 2022, buying an estimated $40.4K and bringing the position to 1,333 shares worth $89K. The position accounts for 0.03% of the portfolio, ranked #389.

Fieldpoint Private Securities first reported a position in MRTX in Q1 2022 and has held it in 2 quarters since. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

  • Fieldpoint Private Securities held 1,333 shares of Mirati Therapeutics, Inc. Common Stock worth $89K as of Q2 2022.
  • Fieldpoint Private Securities bought 635 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $40.4K.
  • Mirati Therapeutics, Inc. Common Stock made up 0.03% of Fieldpoint Private Securities's portfolio in Q2 2022, its #389 holding.
  • Fieldpoint Private Securities first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and has held it in 2 quarters since.
  • 230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.